NC-LENOVO
10.11.2021 15:02:09 CET | Business Wire | Press release
Lenovo™ today announced that DreamWorks Animation has selected Lenovo as its preferred workstation innovation partner to deliver the high-end power and performance needed to bring its next cutting-edge animation feature films to life. This PC collaboration further strengthens the companies’ partnership, as it expands upon the technology leader’s current role as DreamWorks’ data center innovation partner. As part of this multi-year agreement, DreamWorks will deploy Lenovo workstations, including the ThinkStation P620 and ThinkStation P920 , across all departments for the development of content and characters, including the highly anticipated release of the studio’s upcoming film, “The Bad Guys.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005429/en/
The extension of this partnership follows the rollout of a new on-premises Lenovo computing infrastructure designed to transform DreamWorks’ data center into a high-performance, ultra-scalable and sustainable operations center for all of its content creation.
With consumer demand for premium animated content at an all-time high, DreamWorks Animation looked to Lenovo’s Intelligent Devices Group to find innovative workstation solutions that could keep up with its ever-scaling ambitions, increasingly complex workflows and faster production timelines. Designed for high productivity, Lenovo workstations are engineered for power, performance and industry-leading reliability that allow artists to bring their creative ideas to life.
“At DreamWorks, the ability to operate our workflows at the speed of our creative thought process is critical in capturing those instant moments of expression that shape the unforgettable experiences our animators and creative professionals develop. Workstations need to exceed the demands of our artists’ relentless imaginations. Hardware needs to be an enabler; harnessing performance and speed to meet their expectations,” said Bill Ballew, Chief Technology Officer at DreamWorks. “We had the opportunity to test Lenovo’s ThinkStation P620 workstation and realized it’s a game changer for our workflows. Built on the AMD Ryzen™ Threadripper™ PRO architecture, the ThinkStation P620 drives new and improved performance for multi-threaded application environments that our team can take full advantage of.”
From 3D modeling, rigging, surfacing, and simulations to high performance animation and creating hyper-photorealistic renderings, DreamWorks Animation specialists, artists and engineers alike leverage high performance compute capabilities. By relying on the flexibility and future-proofed platforms that Lenovo’s workstations deliver, the DreamWorks’ team can focus on their creative ambitions knowing they are equipped with the world-class technology necessary to meet those complex workflows - now and in the years ahead. In addition to the Lenovo ThinkStation P620, DreamWorks Animation will also be able to take advantage of Lenovo’s most advanced dual processor workstation, the ThinkStation P920. Built with the latest generation of Intel® Xeon® processors, the workstation’s extreme performance will help DreamWorks accelerate their most challenging workflows in a production studio environment.
“We’re excited to expand our partnership with DreamWorks Animation and equip them with workstations that help accelerate their increasingly demanding workflows,” said Rob Herman, Vice President of Lenovo’s Workstation and Client AI Business Unit. “Our workstation collaboration further exemplifies Lenovo’s ability to holistically support our customers with the most advanced technology solutions available, allowing them to innovate faster and transform their respective industries.”
To learn more about how DreamWorks Animation is strengthening its partnership with Lenovo to bring about the next evolution of production, visit: https://techtoday.lenovo.com/us/en/workstations
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .
LENOVO, THINKSTATION and THINKPAD are trademarks of Lenovo. AMD and RYZEN™ are trademarks of Advanced Micro Devices, Inc. Intel, Intel Core and vPro are trademarks of Intel Corporation or its subsidiaries in the U.S. and/or other countries. ©2021, Lenovo Group Limited.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005429/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom